Buybacks largely absorbed by stock pay. Stock-based pay expense $18M vs $20M spent repurchasing shares over the 3 fiscal years to FY Aug 2025. Shares outstanding changed −0.2% from August 2022 to June 2026.
Over three fiscal years Simulations Plus recorded $18M of stock-based pay expense and spent $20M repurchasing shares (repurchases can include shares withheld to cover employees' taxes). The share count barely moved (−0.2%), so much of the repurchasing offset new employee shares rather than shrinking the count.Over three fiscal years Simulations Plus recorded $18M of stock-based pay expense and spent $20M repurchasing shares. The share count barely moved (−0.2%), so much of the repurchasing offset new employee shares rather than shrinking the count.
Earnings turned from a loss to a profit. Profit per share this year after a loss last year.
Simulations Plus made a profit per share in its latest year after a loss the year before.
Cash flow well above reported profit. Free cash flow is 3.0× reported profit.
Free cash flow is 3.0× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $42M in FY Aug 2020 to $79M in FY Aug 2025.
Simulations Plus's fiscal-year revenue rose in each of the five years to FY Aug 2025, from $42M to $79M.
Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 1.07Sector median: 0.2215 · MAD: 0.2039
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Simulations Plus
Is Simulations Plus getting weaker?
Its latest SEC filing (Jul 9, 2026) got stronger: turned profitable over the last 12 months; operating margin rose 97.5 points to 14.0%. Its overall score is unchanged at 66/100 since Oct 28, 2026.
How is Simulations Plus valued vs its peers?
Priced about in line with its peers. Valuation scores 52/100 against 1,393 healthcare peers.
Is Simulations Plus growing?
Yes, faster than most of its peers. Growth scores 79/100 against 1,393 healthcare peers.3-year revenue growth 13.8% vs a peer median of 5.8% (stronger than 71% of peers).3-year revenue growth 13.8% vs peers 5.8% (stronger than 71% of peers).Revenue growth 2.1% vs a peer median of 6.1% (weaker than 64% of peers).Revenue growth 2.1% vs peers 6.1% (weaker than 64% of peers).
How profitable is Simulations Plus?
More profitable than most of its peers. Profitability scores 68/100 against 1,393 healthcare peers.Return on assets 5.3% vs a peer median of 1.7% (stronger than 74% of peers).Return on assets 5.3% vs peers 1.7% (stronger than 74% of peers).
How risky is Simulations Plus?
Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Debt / equity <0.01× vs a peer median of 0.22× (stronger than 94% of peers).Debt / equity <0.01× vs peers 0.22× (stronger than 94% of peers).Beta 1.33 vs a peer median of 0.63 (weaker than 83% of peers).Beta 1.33 vs peers 0.63 (weaker than 83% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended May 31, 2026 · filed Jul 9, 2026 · compared with the quarter ended Feb 28, 2026
Got stronger
Turned profitable over the last 12 months
Operating margin rose 97.5 points to 14.0%
Previous quarter
Latest quarter
Change
Revenue (12 months)
80.5M USD
82.1M USD
+1.9%
Net income (12 months)
−62.8M USD
8.1M USD
turned positive
Operating margin
-83.5%
14.0%
+97.5 pts
Free cash flow (12 months)
23.8M USD
24.5M USD
+3.2%
Cash
25.7M USD
35.3M USD
+37.3%
Shares outstanding
20.2M
20.2M
+0.1%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Health Information Services companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY Aug 2021
FY Aug 2022
FY Aug 2023
FY Aug 2024
FY Aug 2025
Change
Gross margin
77.2%
79.9%
80.5%
61.6%
58.4%
▼ 3.3 pts
Operating margin
24.2%
27.7%
14.6%
8.8%
-89.3%
▼ 98 pts
Net margin
21.1%
23.2%
16.7%
14.2%
-81.7%
▼ 96 pts
Return on assets (ROA)
5.4%
6.6%
5.4%
5.1%
-49.1%
▼ 54 pts
Return on equity (ROE)
5.9%
7.0%
5.9%
5.5%
-51.9%
▼ 57 pts
Free cash flow margin
37.8%
31.7%
35.9%
18.2%
22.0%
▲ 3.8 pts
Current ratio
12.04×
18.98×
10.88×
3.26×
7.67×
▲ 135%
Interest coverage
511.50×
—
—
—
—
—
SLP price history
Price history is added with the daily price update and will appear after the next one.